Intravenous antiplatelet therapy may improve heart function in cardiogenic shock patients compared to oral medication

AI Summary

A report describes research suggesting intravenous antiplatelet therapy may improve heart function in people who survive a heart attack complicated by cardiogenic shock. Better heart function could reduce their long-term risk of heart failure.

Patients who survive cardiogenic shock after a heart attack are among the highest-risk patients and have a significant risk of developing heart failure. Any improvement of heart function should reduce their risk of developing heart failure in the long term.